Want to see DNTH full AI Analyst Report?
Top Page
Dianthus Therapeutics
(NASDAQ:DNTH)
Select Model
Select Model
Rating:58Neutral
Price Target:
$86.00
▼(-18.75% Downside)
Action:Reiterated
Date:08/05/26
The score is held back primarily by weak financial performance—ongoing losses and increasing cash burn—despite a strong, low-debt balance sheet. Technically, the stock shows solid upward momentum (trading above key moving averages with a positive MACD), and recent clinical progress is a meaningful positive, but traditional valuation remains unattractive due to unprofitability and no dividend.
Positive Factors
Low leverage and expanding asset base
Extremely low leverage reduces financial risk and preserves flexibility while Dianthus funds research and operations. Expansion in equity and total assets may provide a stronger capital base for advancing its pipeline, although that capital is not yet producing positive returns.
Negative Factors
No recurring commercial revenue
Without marketed products, Dianthus lacks a recurring revenue engine and remains dependent on financing activities to fund development. This makes future operating performance reliant on clinical and regulatory execution before commercial cash inflows can become durable.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and expanding asset base
Extremely low leverage reduces financial risk and preserves flexibility while Dianthus funds research and operations. Expansion in equity and total assets may provide a stronger capital base for advancing its pipeline, although that capital is not yet producing positive returns.
Read all positive factors
Dianthus Therapeutics (DNTH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.61B
Dividend YieldN/A
Average Volume (3M)809.49K
Price to Earnings (P/E)―
Beta (1Y)0.82
Revenue Growth-60.77%
EPS Growth-27.57%
CountryUS
Employees92
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.13
Shares Outstanding55,934,380
10 Day Avg. Volume826,970
30 Day Avg. Volume809,492
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)3.16
Price to Sales (P/S)764.98
P/FCF Ratio-12.05
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue2.40K
Enterprise Value/Gross Profit2.50K
Enterprise Value/Ebitda-154.97
Forecast
1Y Price Target
$142.82Price Target Upside34.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-3.79
Revenue Forecast (FY)$1.88M
Dianthus Therapeutics Business Overview & Revenue Model
Company Description
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with exten...
How the Company Makes Money
As a clinical-stage biotechnology company, Dianthus Therapeutics does not have product sales and therefore does not generate recurring commercial revenue from marketed therapies. The company primarily funds operations through financing activities ...
Dianthus Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.90M | 2.04M | 6.24M | 2.83M | 6.42M | 1.48M |
| Gross Profit | 1.83M | 2.04M | 6.24M | 2.83M | 6.42M | 1.48M |
| EBITDA | -29.53M | -161.91M | -84.56M | -43.20M | -28.33M | -11.09M |
| Net Income | -29.91M | -162.34M | -84.97M | -43.55M | -28.48M | -13.11M |
Balance Sheet | ||||||
| Total Assets | 1.21B | 530.92M | 374.01M | 179.41M | 83.11M | 189.93M |
| Cash, Cash Equivalents and Short-Term Investments | 886.81M | 404.30M | 275.24M | 173.72M | 75.49M | 176.93M |
| Total Debt | 1.29M | 1.39M | 1.49M | 585.00K | 788.00K | 0.00 |
| Total Liabilities | 41.25M | 37.52M | 21.53M | 10.54M | 9.45M | 17.26M |
| Stockholders Equity | 1.17B | 493.40M | 352.48M | 168.87M | 73.66M | 172.67M |
Cash Flow | ||||||
| Free Cash Flow | -155.71M | -129.27M | -78.28M | -36.97M | -29.21M | -60.80M |
| Operating Cash Flow | -155.38M | -129.06M | -78.18M | -36.86M | -29.07M | -59.53M |
| Investing Cash Flow | -776.56M | -122.83M | -286.81M | 20.25M | -59.82M | 43.43M |
| Financing Cash Flow | 1.03B | 280.13M | 255.62M | 133.57M | 96.68M | 89.60M |
Dianthus Therapeutics Technical Analysis
Negative
105.84
Price Trends
102.62
Negative
97.43
Negative
82.21
Positive
Market Momentum
-5.60
Positive
22.99
Positive
14.60
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DNTH, the sentiment is Negative. The current price of 105.84 is above the 20-day moving average (MA) of 92.15, above the 50-day MA of 102.62, and above the 200-day MA of 82.21, indicating a neutral trend. The MACD of -5.60 indicates Positive momentum. The RSI at 22.99 is Positive, neither overbought nor oversold. The STOCH value of 14.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DNTH.
Dianthus Therapeutics Risk Analysis
Dianthus Therapeutics disclosed 72 risk factors in its most recent earnings report. Dianthus Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Dianthus Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $4.61B | -634.08 | -3.51% | ― | -60.77% | -27.57% | |
58 Neutral | $1.44B | 10.38 | -109.40% | ― | ― | ― | |
58 Neutral | $4.91B | -115.83 | -55.79% | ― | 77.12% | 64.40% | |
55 Neutral | $2.11B | -5.25 | -61.35% | ― | 23220.33% | 13.06% | |
53 Neutral | $2.58B | -9.79 | -38.33% | ― | -88.87% | -35.06% | |
53 Neutral | $2.15B | -5.07 | -84.13% | ― | ― | -63.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
DNTH
Dianthus Therapeutics
82.37
47.95
139.31%
OMER
Omeros
19.83
15.64
373.27%
TVTX
Travere Therapeutics
52.13
25.93
98.95%
VRDN
Viridian Therapeutics
18.66
-2.71
-12.68%
NAMS
NewAmsterdam Pharma Company
21.58
-15.58
-41.92%
VERA
Vera Therapeutics
29.88
-0.61
-2.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.